• 1
    Genton P. When antiepileptic drugs aggravate epilepsy. Brain Dev 2000;22: 7580.
  • 2
    Holmes LB, Harvey EA, Coull BA, et al. The teratogenicity of anticonvulsant drugs. N Engl J Med 2001;344: 11321138.
  • 3
    Anderson GD. A mechanistic approach to antiepileptic drug interactions. Ann Pharmacother 1998;32: 554563.
  • 4
    Tanaka E. Clinically significant pharmacokinetic drug interactions between antiepileptic drugs. J Clin Pharm Ther 1999;24: 8792.
  • 5
    Cazali N, Tran A, Treluyer JM, et al. Inhibitory effect of stiripentol on carbamazepine and saquinavir metabolism in human. Br J Clin Pharmacol 2003;56: 526536.
  • 6
    Chiron C, Marchand MC, Tran A, et al. Stiripentol in severe myoclonic epilepsy in infancy: a randomised placebo-controlled syndrome-dedicated trial: STICLO study group. Lancet 2000;356: 16381642.
  • 7
    Finnell RH, Bennett GD, Slattery JT, et al. Effect of treatment with phenobarbital and stiripentol on carbamazepine-induced teratogenicity and reactive metabolite formation. Teratology 1995;52: 324332.
  • 8
    Levy RH, Rettenmeier AW, Anderson GD, et al. Effects of polytherapy with phenytoin, carbamazepine, and stiripentol on formation of 4-ene-valproate, a hepatotoxic metabolite of valproic acid. Clin Pharmacol Ther 1990;48: 225225.
  • 9
    Levy RH, Loiseau P, Guyot M, et al. Stiripentol kinetics in epilepsy: nonlinearity and interactions. Clin Pharmacol Ther 1984;36: 661669.
  • 10
    Thanh TN, Chiron C, Dellatolas G, et al. [Long-term efficacy and tolerance of stiripentol in severe myoclonic epilepsy of infancy (Dravet's syndrome)]. Arch Pediatr 2002;9: 11201127.
  • 11
    Perez J, Chiron C, Musial C, et al. Stiripentol: efficacy and tolerability in children with epilepsy. Epilepsia 1999;40: 16181626.
  • 12
    Poisson M, Huguet F, Savattier A, et al. A new type of anticonvulsant, stiripentol: pharmacological profile and neurochemical study. Arzneimittelforschung 1984;34: 199204.
  • 13
    Shen DD, Levy RH, Moor MJ, et al. Efficacy of stiripentol in the intravenous pentylenetetrazol infusion seizure model in the rat. Epilepsy Res 1990;7: 4048.
  • 14
    Lockard JS, Levy RH, Rhodes PH, et al. Stiripentol in acute/chronic efficacy tests in monkey model. Epilepsia 1985;26: 704712.
  • 15
    Wegmann R, Ilies A, Aurousseau M. [Pharmaco-cellular enzymology of the mechanism of action of stiripentol in cardiazol-induced epilepsy, III: protein, nucleoprotein, lipid, and proteoglycan metabolism]. Cell Mol Biol 1978;23: 455480.
  • 16
    Tran A, Vauzelle-Kervroedan F, Rey E, et al. Effect of stiripentol on carbamazepine plasma concentration and metabolism in epileptic children. Eur J Clin Pharmacol 1996;50: 497500.
  • 17
    Farwell JR, Anderson GD, Kerr BM, et al. Stiripentol in atypical absence seizures in children: an open trial. Epilepsia 1993;34: 305311.
  • 18
    Solis JM, Nicoll RA. Postsynaptic action of endogenous GABA released by nipecotic acid in the hippocampus. Neurosci Lett 1992;147: 1620.
  • 19
    Borden LA, Murali Dhar TG, Smith KE, et al. SK&F 89976-A, CI-966, and NNC-711 are selective for the cloned GABA transporter GAT-1. Eur J Pharmacol 1994;269: 219224.
  • 20
    Suzdak PD, Frederiksen K, Andersen KE, et al. NNC-711, a novel potent and selective gamma-aminobutyric acid uptake inhibitor: pharmacological characterization. Eur J Pharmacol 1992;224: 189198.
  • 21
    Borden LA, Dhar TG, Smith KE, et al. Cloning of the human homologue of the GABA transporter GAT-3 and identification of a novel inhibitor with selectivity for this site. Receptor Channels 1994;2: 207213.
  • 22
    Hofner G, Wanner KT. Evaluation of GABA uptake in subcellular fractions of bovine frontal cortex and brainstem. Neurosci Lett 2004;364: 5357.
  • 23
    Isaacson JS, Solis JM, Nicoll RA. Local and diffuse synaptic actions of GABA in the hippocampus. Neuron 1993;10: 165175.
  • 24
    Draguhn A, Heinemann U. Different mechanisms regulate IPSC kinetics in early postnatal and juvenile hippocampal granule cells. J Neurophysiol 1996;76: 39833993.
  • 25
    Sipila S, Huttu K, Voipio J, et al. GABA IA transporter-1 modulates GABAergic transmission in the immature hippocampus. J Neurosci 2004;24: 58775880.
  • 26
    Frahm C, Engel D, Draguhn A. Efficacy of background GABA uptake in rat hippocampal slices. Neuroreport 2001;12: 15931596.
  • 27
    Nakamura F, Suzuki S, Nishimura S, et al. Effects of clobazam and its active metabolite on GABA-activated currents in rat cerebral neurons in culture. Epilepsia 1996;37: 728735.
  • 28
    Cunningham MO, Woodhall GL, Jones RSG. Valproate modifies spontaneous excitation and inhibition at cortical synapses in vitro. Neuropharmacology 2003;45: 907917.
  • 29
    Hollrigel GS, Soltesz I. Slow kinetics of miniature IPSCs during early postnatal development in granule cells of the dentate gyrus. J Neurosci 1997;17: 511928.
  • 30
    Cohen AS, Lin DD, Quirk GL, et al. Dentate granule cell GABA(A) receptors in epileptic hippocampus: enhanced synaptic efficacy and altered pharmacology. Eur J Neurosci 2003;17: 16071616.
  • 31
    Defazio T, Hablitz JJ. Zinc and zolpidem modulate mIPSCs in rat neocortical pyramidal neurons. J Neurophysiol 1998;80: 16701677.
  • 32
    Otis TS, Mody I. Modulation of decay kinetics and frequency of GABAA receptor-mediated spontaneous inhibitory postsynaptic currents in hippocampal neurons. Neuroscience 1992;49: 1332.
  • 33
    Leroy C, Poisbeau P, Keller AF, et al. Pharmacological plasticity of GABA(A) receptors at dentate gyrus synapses in a rat model of temporal lobe epilepsy. J Physiol 2004;557: 473487.
  • 34
    Belelli D, Lambert JJ. Neurosteroids: Endogenous regulators of the GABAA receptor. Nat Rev Neurosci 2005;6: 565575.
  • 35
    Lambert JJ, Belelli D, Peden DR, et al. Neurosteroid modulation of GABAA receptors. Progr Neurobiol 2003;71: 6780.
  • 36
    Lambert JJ, Belelli D, Hill-Venning C, et al. Neurosteroids and GABAA receptor function. Trends Pharmacol Sci 1995;16: 295303.
  • 37
    Harney SC, Frenguelli BG, Lambert JJ. Phosphorylation influences neurosteroid modulation of synaptic GABAA receptors in rat CA1 and dentate gyrus neurones. Neuropharmacology 2003;45: 873883.
  • 38
    Park-Chung M, Malayev A, Purdy RH, et al. Sulfated and unsulfated steroids modulate gamma-aminobutyric acidA receptor function through distinct sites. Brain Res 1999;830: 7287.
  • 39
    Sullivan SD, Moenter SM. Neurosteroids alter gamma-aminobutyric acid postsynaptic currents in gonadotropin-releasing hormone neurons: a possible mechanism for direct steroidal control. Endocrinology 2003;144: 43664375.
  • 40
    Zhang L, Weiner JL, Carlen PL. Potentiation of gamma-aminobutyric acid type A receptor-mediated synaptic currents by pentobarbital and diazepam in immature hippocampal CA1 neurons. J Pharmacol Exp Ther 1993;266: 12271235.
  • 41
    Rovira C, Ben-Ari Y. Developmental study of miniature IPSCs of CA3 hippocampal cells: modulation by midazolam. Brain Res Dev Brain Res 1999;114: 7988.
  • 42
    Lim MS, Lindquist CE, Birnir B. Effects of pentobarbital on GABA-activated currents in acutely-isolated rat dentate gyrus granule neurons. Neurosci Lett 2003;353: 139142.
  • 43
    Dalziel JE, Cox GB, Gage PW, et al. Mutant human α11(T262Q) GABA(A) receptors are directly activated but not modulated by pentobarbital. Eur J Pharmacol 1999;385: 283286.
  • 44
    Rho JM, Donevan SD, Rogawski MA. Direct activation of GABAA receptors by barbiturates in cultured rat hippocampal neurons. J Physiol (Lond) 1996;497: 509522.
  • 45
    Thompson SA, Whiting PJ, Wafford KA. Barbiturate interactions at the human GABAA receptor: dependence on receptor subunit combination. Br J Pharmacol 1996;117: 5217.
  • 46
    Eghbali M, Gage PW, Birnir B. Pentobarbital modulates gamma-aminobutyric acid-activated single-channel conductance in rat cultured hippocampal neurons. Mol Pharmacol 2000;58: 463469.
  • 47
    Engel D, Schmitz D, Gloveli T, et al. Laminar difference in GABA uptake and GAT-1 expression in rat CA1. J Physiol (Lond) 1998;512: 643649.
  • 48
    Lehmenkuhler A, Sykova E, Svoboda J, et al. Extracellular space parameters in the rat neocortex and subcortical white matter during postnatal development determined by diffusion analysis. Neuroscience 1993;55: 339351.
  • 49
    Holland KD, Canney DJ, Rothman SM, et al. Physiological modulation of the GABA receptor by convulsant and anticonvulsant barbiturates in cultured rat hippocampal neurons. Brain Res 1990;516: 147150.
  • 50
    Twyman RE, Rogers CJ, Macdonald RL. Differential regulation of gamma-aminobutyric acid receptor channels by diazepam and phenobarbital. Ann Neurol 1989;25: 213220.
  • 51
    Bikker JA, Kubanek J, Weaver DF. Quantum pharmacologic studies applicable to the design of anticonvulsants: theoretical conformational analysis and structure-activity studies of barbiturates. Epilepsia 1994;35: 411425.
  • 52
    Fatt P, Katz B. Spontaneous subthreshold activity at motor nerve endings. J Physiol 1952;117: 109128.
  • 53
    Duffy S, Nguyen PV, Baker GB. Phenylethylidenehydrazine, a novel GABA-transaminase inhibitor, reduces epileptiform activity in rat hippocampal slices. Neuroscience 2004;126: 423432.
  • 54
    Loscher W, Horstermann D. Differential effects of vigabatrin, gamma-acetylenic GABA, aminooxyacetic acid, and valproate on levels of various amino acids in rat brain regions and plasma. Naunyn Schmiedebergs Arch Pharmacol 1994;349: 270278.
  • 55
    Wood JD, Kurylo E, Lane R. γ-Aminobutyric acid release from synaptosomes prepared from rats treated with isonicotinic acid hydrazide and gabaculine. J Neurochem 1988;50: 18391843.
  • 56
    Carmona E, Gomes C, Trolin G. Effect of aminooxyacetic acid (AOAA) on GABA levels in some parts of the rat brain. Naunyn Schmiedebergs Arch Pharmacol 1980;312: 5155.
  • 57
    Loiseau P, Strube E, Tor J, et al. [Neurophysiological and therapeutic evaluation of stiripentol in epilepsy: preliminary results]. Rev Neurol (Paris) 1988;144: 165172.
  • 58
    Chiron C, Tonnelier S, Rey E, et al. Stiripentol in childhood partial epilepsy: a randomized placebo-controlled trial with enrichment and withdrawal design. J Child Neurol 2006 (in press).
  • 59
    Czuczwar SJ, Patsalos PN. The new generation of GABA enhancers: potential in the treatment of epilepsy. CNS Drugs 2001;15: 339350.
  • 60
    Treiman DM. GABAergic mechanisms in epilepsy. Epilepsia 2001;42(suppl 3):812.
  • 61
    Gasior M, Ungard JT, Witkin JM. Preclinical evaluation of newly approved and potential antiepileptic drugs against cocaine-induced seizures. J Pharmacol Exp Ther 1999;290: 11481156.
  • 62
    Schulz DW, Macdonald RL. Barbiturate enhancement of GABA-mediated inhibition and activation of chloride ion conductance: correlation with anticonvulsant and anesthetic actions. Brain Res 1981;209: 177188.